CORD-19:932bcdd2f6c6d487386e8bf983e4874387771be1 / 53156-53605 JSONTXT

{"project":"CORD-19-Sentences","denotations":[{"id":"T86938","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T93162","span":{"begin":102,"end":449},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Gangliosides as autoantibody targets at the neuromuscular junction in immune-mediated neuropathies H. Willison University of Glasgow, Glasgow, Scotland Progress in our understanding of the Guillain-Barré syndromes has been greatly accelerated by the identification of humoral responses to glycolipids in a significant proportion of cases, and the identification of molecular mimicry with preceding infections as a key mechanism of disease induction."}

{"project":"Epistemic_Statements","denotations":[{"id":"T132","span":{"begin":0,"end":449},"obj":"Epistemic_statement"}],"text":"Gangliosides as autoantibody targets at the neuromuscular junction in immune-mediated neuropathies H. Willison University of Glasgow, Glasgow, Scotland Progress in our understanding of the Guillain-Barré syndromes has been greatly accelerated by the identification of humoral responses to glycolipids in a significant proportion of cases, and the identification of molecular mimicry with preceding infections as a key mechanism of disease induction."}

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T25","span":{"begin":0,"end":101},"obj":"Sentence"},{"id":"T26","span":{"begin":102,"end":449},"obj":"Sentence"}],"text":"Gangliosides as autoantibody targets at the neuromuscular junction in immune-mediated neuropathies H. Willison University of Glasgow, Glasgow, Scotland Progress in our understanding of the Guillain-Barré syndromes has been greatly accelerated by the identification of humoral responses to glycolipids in a significant proportion of cases, and the identification of molecular mimicry with preceding infections as a key mechanism of disease induction."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T218","span":{"begin":189,"end":213},"obj":"Disease"},{"id":"T219","span":{"begin":398,"end":408},"obj":"Disease"},{"id":"T88951","span":{"begin":189,"end":213},"obj":"Disease"},{"id":"T30496","span":{"begin":398,"end":408},"obj":"Disease"}],"attributes":[{"id":"A218","pred":"mondo_id","subj":"T218","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A219","pred":"mondo_id","subj":"T219","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A34858","pred":"mondo_id","subj":"T88951","obj":"http://purl.obolibrary.org/obo/MONDO_0016218"},{"id":"A70743","pred":"mondo_id","subj":"T30496","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"Gangliosides as autoantibody targets at the neuromuscular junction in immune-mediated neuropathies H. Willison University of Glasgow, Glasgow, Scotland Progress in our understanding of the Guillain-Barré syndromes has been greatly accelerated by the identification of humoral responses to glycolipids in a significant proportion of cases, and the identification of molecular mimicry with preceding infections as a key mechanism of disease induction."}